期刊文献+

乳腺癌^(18)F-FDG摄取值与临床病理及生物指标的关联 被引量:1

Relationship of uptake value of ^(18)F-FDG with clinicaopathology and biological indicators in patients with breast cancer
原文传递
导出
摘要 目的探讨乳腺癌18 F-脱氧葡萄糖(18 F-FDG)摄取值与临床病理及生物指标的关联。方法回顾性分析20例乳腺癌患者的18F-FDG最大标准摄取值(SUVmax)与肿瘤大小、病理分级、雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(Her-2)和Ki-67表达之间的关系。结果瘤体直径与SUVmax值呈正相关(r=0.704,P<0.05)。13例高分化患者SUVmax值低于7例低分化患者(4.68±2.05vs.8.63±3.98)(P<0.05)。ER、PR和Her-2表达水平与SUVmax值无相关性(r=-0.092,r=-0.010和r=0.341,P>0.05),Ki-67表达水平与SUVmax值密切相关(r=0.483,P<0.05)。结论乳腺癌的病灶大小、病理分级和Ki-67表达与18 F-FDG摄取值密切相关;SUVmax在预后评估中有一定的临床应用价值。 Objective To investigate the relationship between the uptake value of 18 F fluorodeoxyglucose(18F-FDG) and clinicaopathology and biological indicators in the patients with breast cancer. Methods The relationship of the maximum standandized uptake value (SUVmax) of 18F-FDG with tumor size, tumor grade and expressions of estrogen receptor (ER), progesterone receptor(PR) ,human epidermal receptor 2 (Her-2) and Ki-67 in 20 patients with breast cancer were retrospectively analyzed. Results SUV was positively correlated to the tumor diameter(r=0. 704, P〈0. 05). SUVmax was higher in 13 patients with high differentiation than that in in 7 patients with low differentiation (4. 68 ± 2.05 vs. 8.63 ± 3. 98) ( P(0. 05 ). There was no significant correlation between SUV,±x and the expressions of ER, PR and Her-2 (r=-0. 092, r=-0. 010 and r=0. 341, P〉0. 05). The expression of Ki-67 was closely related to SUVmax (r=0. 483, P〈0. 05). Conclusion The uptake value of 18F-FIX; is closely associated with tumor size, tumor grade and Ki-67 expression in patients with breast cancer. SUVmax can be taken as an indicator in evaluating the clinical prognosis of breast cancer.
出处 《江苏医药》 CAS 北大核心 2013年第24期2974-2976,共3页 Jiangsu Medical Journal
基金 国家自然科学基金青年基金(81202032)
关键词 乳腺癌 18F脱氧葡萄糖 Breast cancer 18 F fluorodeoxyglucose
  • 相关文献

参考文献10

  • 1Li J, Zhang BIN, Fan JH, et al. A nation-wide multieenter 10-year ( 1999-2008 ) retrospective clinical epidemiological study of female breast cancer in China [J]. BMC Cancer, 2011,11:364.
  • 2Groheux D, Giacchetti St Rubello D, et al. The ewlving role of PET/CT in breast caneer[J]. Nucl Med Commun, 2010, 31(4):271- 273.
  • 3Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18Ffluorodeoxy- glucose positron emission tomography/computed tomography fusion imaging (8F-FDG PET/CT) in primary breast cancer [J]. Jpn J Clin Oncol,2008,38(4) : 250-258.
  • 4Shimoda W, Hayashi M, Murakami K, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer[J]. Breast Cancer,2007,14(3):260-268.
  • 5吴世凯,宋三泰.对乳腺癌雌孕激素受体检测的认识[J].中华乳腺病杂志(电子版),2012,6(3):39-41. 被引量:13
  • 6王若曦,王水.乳腺癌ER、PR及HER-2在原发灶和转移灶之间表达关系的研究进展[J].江苏医药,2013,39(8):958-961. 被引量:11
  • 7Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer [J ]. Pharm Res, 2012, 29 ( 3 ) : 770-781.
  • 8Osborne JR,Port E,Gonen M,et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis[J]. J Nuel Med,2010,51(4): 543-550.
  • 9Kim BS, Sung SH. Usefulness of 18F-FI)G uptake with clinicopathologic and immunohistochemical prognostic factors in breast eancer[J]. Ann Nucl Med, 2012,26(2) : 175-183.
  • 10Sanli Y,Kuyumcu S,Ozkan ZG,et al. Increased FDG uptake in breast cancer is associated with prognostic factors[J]. Ann Nucl Med,2012,26(4) :345-350.

二级参考文献35

  • 1Hammond ME, Hayes DF, Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[ J ]. J Clin Oncol, 2010,28(16) :2784-2795.
  • 2McGuire W, Carbone PP, Sears ME, et al. Estrogen receptors in human breast cancer [ J ]//McGuire WL, Carbone PP, Vollmer EP. Estrogen receptors in human breast cancer. New York: Raven Press, 1975 : 1-7.
  • 3Cowen PN, Teasdale J, Jackson P, et al. Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay[ J]. Histopathology, 1990,17 (4) :319-325.
  • 4Badve SS, Baehner FL, Gray RP, et al. Estrogen and progesterone receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory[ J]. J Clin Oncol, 2008,26(15) :2473-2481.
  • 5Osborne CK, Yochmowitz MG, Knight WA 3rd, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer[J]. Cancer,1980,46(12) :2884-2888.
  • 6Knight WA 3rd, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer [ J ]. Clin Endocrinol Metab,1980 ,9 (2) :361-368.
  • 7Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistoehemistry is superior to the ligand-bindingassay for predicting response to adjuvant endocrine therapy in breast cancer[ J ]. J Clin 0nco1,1999,17 (5) : 1474-1481.
  • 8Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study [ J ]. Mod Patho1,2004,17 (5) : 1545-1554.
  • 9Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[ J]. Clin Cancer Res, 2006,12( 15 ) : 4614-4618.
  • 10Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer [ J ]. Breast Cancer,2006,13 ( 1 ) :74-83.

共引文献21

同被引文献3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部